TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1446996

Group type: EXPERIMENTAL
Intervention: Propranolol treatment for 4 to 6 weeks after a 2-week placebo phase
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 38
Study: 2870353

Group type: EXPERIMENTAL
Intervention: LHRH (1.2 mg/day intranasally)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LHRH (after second course in open study)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LHRH
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LHRH and human chorionic gonadotropin (before treatment)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 252
Study: 30870556

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control
Number of subjects: 278
Study: 28661264

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg once daily for 15 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study: 25617983

Group type: EXPERIMENTAL
Intervention: alglucosidase alfa 20 mg/kg/week
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: alglucosidase alfa 40 mg/kg/2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: standard ERT (alglucosidase alfa 20 mg/kg/2 weeks)
Number of subjects: 13
Study: 23884299

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H-MRS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Baseline MRS results
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Longitudinal changes of MRS results
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MRS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NAA/Cre
Number of subjects: 22
Study: 21708809

Group type: EXPERIMENTAL
Intervention: High-DHA diet
Number of subjects: 657

Group type: COMPARATOR
Intervention: Standard-DHA diet
Number of subjects: 657
Study: 19538690

Group type: EXPERIMENTAL
Intervention: Disorder-specific psychotherapies (CBT, interpersonal, family, and group therapies)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Group psychoeducation trial
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Adjunctive psychotherapies
Number of subjects: 19
Study: 17426802

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.10 mg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.60 mg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.90 mg.kg(‐1)
Number of subjects: 120
Study: 15589220

Group type: EXPERIMENTAL
Intervention: Gross motor (GM) activity group (bone loading, large muscle exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine motor (FM) activity group (arts and crafts program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gross motor (GM) activity group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine motor (FM) activity group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gross motor (GM) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine motor (FM) group
Number of subjects: 0
Study: 11576567

Group type: EXPERIMENTAL
Intervention: Oral sulindac (100 mg) every 12 hours until 34 weeks' gestation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo every 12 hours until 34 weeks' gestation
Number of subjects: 95
Study: 9663440

Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol-containing chewing gum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucrose-sweetened chewing gum
Number of subjects: 30
Study: 7820328

Group type: EXPERIMENTAL
Intervention: Test drug (piracetam)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference drug (piracetam)
Number of subjects: 16
Study: 3344179

Group type: EXPERIMENTAL
Intervention: Iron-fortified formulas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-iron-fortified formulas
Number of subjects: 0
Study: 1824271

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) after conditioning with cyclophosphamide (CY) total body irradiation (TBI) plus (n = 27), VP‐16‐TBI (n = 23), and CY‐TBI and ARA‐C (n = 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 51
Study: 787460

Group type: EXPERIMENTAL
Intervention: Betahistine (16 mg t.i.d.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 22
Study: 30908420

Group type: EXPERIMENTAL
Intervention: Vortex approach
Number of subjects: 67

Group type: COMPARATOR
Intervention: ASA algorithm
Number of subjects: 67
Study: 29280453

Group type: EXPERIMENTAL
Intervention: Topical OTD70DERM (RGTA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26523032

Group type: EXPERIMENTAL
Intervention: Abatacept (ABA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23175561

Group type: EXPERIMENTAL
Intervention: Mefloquine IPTp
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 65
Study: 21605121

Group type: EXPERIMENTAL
Intervention: Enactive encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task repetition
Number of subjects: 0
Study: 19539211

Group type: EXPERIMENTAL
Intervention: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids
Number of subjects: 32

Group type: COMPARATOR
Intervention: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg
Number of subjects: 32
Study: 16927304

Group type: EXPERIMENTAL
Intervention: Dutasteride 3.5 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 81
Study: 15322856

Group type: EXPERIMENTAL
Intervention: IVT(+50%DeltaT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IVT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IVT(‐50%DeltaT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 12
Study: 11455982

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Number of subjects: 249
Study: 9737221

Group type: EXPERIMENTAL
Intervention: Dual-site atrial pacing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Single-site atrial pacing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Support-only pacing
Number of subjects: 9
Study: 8069675

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3354254

Group type: EXPERIMENTAL
Intervention: Paediatric attenuated influenza vaccine (two doses, intranasally, 1 month apart)
Number of subjects: 43
Study: 29307094

Group type: EXPERIMENTAL
Intervention: Letter with individualized fracture risk and educational brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care only (control)
Number of subjects: 7749
Study: 28704363

Group type: EXPERIMENTAL
Intervention: U-MDT (dapsone+rifampicin+clofazimine for six months)
Number of subjects: 613

Group type: COMPARATOR
Intervention: R-MDT (dapsone+rifampicin+clofazimine for 12 months)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: U-MDT
Number of subjects: 613

Group type: COMPARATOR
Intervention: R-MDT
Number of subjects: 613
Study: 26222759

Group type: EXPERIMENTAL
Intervention: Aromatherapy (lavender oil) in addition to standard medical treatment (diclofenac sodium, 75 mg intramuscularly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical therapy (diclofenac sodium, 75 mg intramuscularly)
Number of subjects: 100
Study: 24218347

Group type: EXPERIMENTAL
Intervention: Telehealth intervention with diabetes educator nurse via in-home broadband communication device
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 12
Study: 21443293

Group type: EXPERIMENTAL
Intervention: Combination Behavioral Intervention (CBI) only
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Study medications (naltrexone, acamprosate, naltrexone + acamprosate, placebo) with medication management (MM)
Number of subjects: 1383
Study: 19015204

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03% applied once daily, 3 times per week
Number of subjects: 206

Group type: COMPARATOR
Intervention: Vehicle applied once daily, 3 times per week
Number of subjects: 206
Study: 16818032

Group type: EXPERIMENTAL
Intervention: P supplementation started the day before oocyte retrieval (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: P supplementation started on the day of oocyte retrieval (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: P supplementation started 1 day after egg retrieval (Group C)
Number of subjects: 300
Study: 12647487

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (HRT)
Number of subjects: 0
Study: 11561118

Group type: EXPERIMENTAL
Intervention: Active homeopathy (6cH and/or 30cH dilutions)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Active homeopathy
Number of subjects: 112
Study: 9782217

Group type: EXPERIMENTAL
Intervention: Dey combination solution (albuterol-ipratropium)
Number of subjects: 863
Study: 8145958

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg once daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg once daily for 4 weeks
Number of subjects: 20
Study: 3139877

Group type: EXPERIMENTAL
Intervention: Methotrexate 10 mg IM weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium aurothiomalate (GSTM) 50 mg IM weekly
Number of subjects: 40
Study: 31532277

Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intramuscular injection monotherapy (IMIM)
Number of subjects: 43
Study: 30529119

Group type: EXPERIMENTAL
Intervention: Topical heparin treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 66
Study: 27618796

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous amisulpride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 40
Study: 26091244

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted TIV (aTIV)
Number of subjects: 197

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: aTIV after control vaccine
Number of subjects: 197

Group type: COMPARATOR
Intervention: TIV-TIV regimen
Number of subjects: 197

Group type: COMPARATOR
Intervention: TIV-aTIV mixed regimens
Number of subjects: 197
Study: 24334642

Group type: COMPARATOR
Intervention: Traditional written PtGA and GH assessments
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Verbal assessments administered in-person
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Health literacy (HL)
Number of subjects: 300
Study: 21937041

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (AIDS Risk Reduction Model)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Enhanced counseling
Number of subjects: 409
Study: 19294693

Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV) 80 mg/dL for two months (n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment (CT) for two months (n = 11)
Number of subjects: 25
Study: 17180553

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT) procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Burch colposuspension procedure
Number of subjects: 100
Study: 15470336

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 750 mL red wine (13.5% by volume)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of sildenafil and red wine
Number of subjects: 8
Study: 11347776

Group type: EXPERIMENTAL
Intervention: Outpatient geriatric evaluation and management (GEM)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 568
Study: 9475863

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for lidocaine study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for atropine study)
Number of subjects: 0
Study: 7710400

Group type: EXPERIMENTAL
Intervention: Teller Acuity Cards
Number of subjects: 69

Group type: COMPARATOR
Intervention: Snellen visual acuity (gold standard)
Number of subjects: 69
Study: 2693405

Group type: EXPERIMENTAL
Intervention: Nimodipine 40 mg t.i.d.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 912324

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Calcium treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study: 31994752

Group type: EXPERIMENTAL
Intervention: Shared decision-making tool generating personalized predictions of risks and benefits from TJR based on patient-reported outcomes, clinical and demographic data.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 30905430

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention with weekly self-monitoring, tailored feedback on diet and exercise goals, and dietitian and provider counseling.
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention.
Number of subjects: 306
Study: 27838273

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training and mindfulness meditation training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined training (Adaptive WM training + MMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 25784358

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (RM)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus ketorolac
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus verteporfin photodynamic therapy (RV)
Number of subjects: 75
Study: 24026876

Group type: EXPERIMENTAL
Intervention: Cisplatin/pirarubicin (CITA) chemotherapy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with stem cell transplantation (SCT)
Number of subjects: 331

Group type: COMPARATOR
Intervention: CITA regimen
Number of subjects: 331

Group type: COMPARATOR
Intervention: HDC with SCT
Number of subjects: 331
Study: 21415071

Group type: EXPERIMENTAL
Intervention: Mid-regional pro-adrenomedullin (MR-proADM)
Number of subjects: 214
Study: 19154270

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally for 3 days before orthodontic activation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally for 3 days after orthodontic activation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 36
Study: 17410029

Group type: COMPARATOR
Intervention: Gemcitabine (G) 1250 mg/m, given on days 1 and 14, repeated every 28 days for up to four cycles.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin (GCb) 1250 mg/m of G plus carboplatin area under the curve of 3, given on days 1 and 14, repeated every 28 days for up to four cycles.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin (GCb)
Number of subjects: 90
Study: 15478362

Group type: EXPERIMENTAL
Intervention: rhBMP-2-augmented fusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft (control)
Number of subjects: 0
Study: 11479880

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in group III (1760.0 ± 717.5 ng/mL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sVCAM‐1 levels in group III (1932.9 ± 282.6 ng/mL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sVCAM‐1 levels in group II with portal hypertension (PH) (1253.0 ± 245.1 ng/mL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Expression of ICAM‐1 and VCAM‐1
Number of subjects: 35
Study: 9510981

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, 200 mg after a high-fat breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dolasetron mesylate, 200 mg after an overnight fast
Number of subjects: 24
Study: 9063763

Group type: EXPERIMENTAL
Intervention: 1 g. day-1 of allithiamine for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 15
Study: 1946576

Group type: EXPERIMENTAL
Intervention: Theophylline (100 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (25 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (higher dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 20
Study: 7053279

Group type: EXPERIMENTAL
Intervention: Verapamil (240, 360, and 480 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31359053

Group type: EXPERIMENTAL
Intervention: Environmental cleaning bundle
Number of subjects: 11

Group type: COMPARATOR
Intervention: Existing hospital cleaning practices
Number of subjects: 11
Study: 30431384

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) using the AlerHTA app, n = 77.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (CG) with usual intervention, n = 77.
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Overall adherence measured by electronic monitors (MEMSs).
Number of subjects: 154
Study: 28011792

Group type: EXPERIMENTAL
Intervention: Humidified high flow nasal cannula (HFNC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 44
Study: 26595135

Group type: EXPERIMENTAL
Intervention: T+ (SUP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Isocaloric placebo (PL)
Number of subjects: 27
Study: 24245960

Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Double maintenance-dose clopidogrel
Number of subjects: 106
Study: 22586253

Group type: EXPERIMENTAL
Intervention: Arterolane maleate plus piperaquine phosphate (AM-PQP) 150 mg and 750 mg respectively
Number of subjects: 240

Group type: COMPARATOR
Intervention: Coartem (artemether and lumefantrine)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both AM-PQP and Coartem
Number of subjects: 240
Study: 20356489

Group type: EXPERIMENTAL
Intervention: (125)I seeds implantation (n = 31)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (n = 34)
Number of subjects: 66
Study: 18341677

Group type: EXPERIMENTAL
Intervention: Tolevamer potassium sodium 15 g day(-1) for 9 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tolevamer potassium sodium 6 g day(-1) for 9 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15715683

Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB receptor antagonism with BQ123 and BQ788 (10 nmol min(‐1)) during ramipril treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg o.d. for 3 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 37
Study: 13679489

Group type: EXPERIMENTAL
Intervention: Buttonhole puncture technique using a thumbtack-shaped polycarbonate peg for 14 days during HD sessions.
Number of subjects: 37
Study: 10473911

Group type: EXPERIMENTAL
Intervention: Cerebellar infarct (posterior inferior cerebellar artery territory in 9 patients, superior cerebellar artery in 6, anterior inferior cerebellar artery in 2, nonterritorial in 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cerebellar infarct
Number of subjects: 105
Study: 9371403

Group type: EXPERIMENTAL
Intervention: BEP (bleomycin, etoposide, and cisplatin) chemotherapy
Number of subjects: 788

Group type: COMPARATOR
Intervention: Control donors
Number of subjects: 788
Study: 1345033

Group type: EXPERIMENTAL
Intervention: Positive pressure drainage (PPD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional negative pressure drainage (NPD)
Number of subjects: 28
Study: 4019953

Group type: COMPARATOR
Intervention: 6‐methyl‐prednisolone (1 mg/kg) intravenous bolus
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6‐methyl‐prednisolone (32 mg once a day, orally) for 8 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 31228507

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 76
Study: 29522226

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% ophthalmic suspension once daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nepafenac 0.1% ophthalmic suspension three times a day
Number of subjects: 35
Study: 26386921

Group type: EXPERIMENTAL
Intervention: Bosentan 4 mg/kg twice-daily (can be down-titrated to 2 mg/kg if not tolerated)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bosentan 4 mg/kg twice-daily
Number of subjects: 33
Study: 24406660

Group type: EXPERIMENTAL
Intervention: Mind-body integration practices and cooperative activities
Number of subjects: 0
Study: 22994348

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite allergen extracts
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 509
Study: 19574861

Group type: EXPERIMENTAL
Intervention: <0.5 mA stimulation threshold
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 0.5‐0.64 mA stimulation threshold
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: >0.65 mA stimulation threshold
Number of subjects: 69